Incyte Corp. (NASDAQ:INCY) – Analysts at SunTrust Banks upped their FY2016 earnings estimates for Incyte Corp. in a research report issued on Thursday. SunTrust Banks analyst P. Lawson now anticipates that the firm will post earnings of $0.35 per share for the year, up from their prior estimate of $0.32. SunTrust Banks currently has a “Buy” rating and a $105.00 target price on the stock.

Several other research analysts also recently commented on INCY. Royal Bank Of Canada increased their price objective on shares of Incyte Corp. from $106.00 to $113.00 and gave the company an “outperform” rating in a report on Wednesday. JPMorgan Chase & Co. reissued a “buy” rating on shares of Incyte Corp. in a report on Wednesday, September 28th. RBC Capital Markets reissued an “outperform” rating and set a $116.00 price objective on shares of Incyte Corp. in a report on Monday, October 10th. Barclays PLC increased their price objective on shares of Incyte Corp. from $85.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, August 10th. Finally, Piper Jaffray Cos. set a $99.00 price objective on shares of Incyte Corp. and gave the company a “buy” rating in a report on Wednesday, September 28th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and twenty-one have issued a buy rating to the company. The stock has an average rating of “Buy” and an average price target of $105.03.

Earnings History and Estimates for Incyte Corp. (NASDAQ:INCY)

Incyte Corp. (NASDAQ:INCY) opened at 87.10 on Friday. The stock has a market cap of $16.37 billion, a P/E ratio of 236.68 and a beta of 0.54. The stock has a 50 day moving average price of $86.88 and a 200 day moving average price of $81.58. Incyte Corp. has a 12-month low of $55.00 and a 12-month high of $124.98.

Incyte Corp. (NASDAQ:INCY) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported $0.18 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.02) by $0.20. The firm had revenue of $208 million for the quarter, compared to the consensus estimate of $236.91 million. Incyte Corp. had a return on equity of 37.76% and a net margin of 7.87%. The company’s quarterly revenue was up 51.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.05 earnings per share.

In other Incyte Corp. news, EVP Reid M. Huber sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $87.96, for a total value of $879,600.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Paula J. Swain sold 60,000 shares of the firm’s stock in a transaction that occurred on Friday, July 29th. The shares were sold at an average price of $90.00, for a total transaction of $5,400,000.00. Following the completion of the sale, the executive vice president now owns 89,248 shares of the company’s stock, valued at $8,032,320. The disclosure for this sale can be found here. Corporate insiders own 13.70% of the company’s stock.

A number of large investors have recently made changes to their positions in INCY. Pacer Advisors Inc. increased its stake in shares of Incyte Corp. by 1.0% in the second quarter. Pacer Advisors Inc. now owns 5,800 shares of the biopharmaceutical company’s stock valued at $463,000 after buying an additional 55 shares during the period. Addison Capital Co increased its stake in shares of Incyte Corp. by 0.8% in the third quarter. Addison Capital Co now owns 8,441 shares of the biopharmaceutical company’s stock valued at $796,000 after buying an additional 63 shares during the period. Mn Services Vermogensbeheer B.V. increased its stake in shares of Incyte Corp. by 1.7% in the second quarter. Mn Services Vermogensbeheer B.V. now owns 4,256 shares of the biopharmaceutical company’s stock valued at $306,000 after buying an additional 73 shares during the period. CIBC Asset Management Inc increased its stake in shares of Incyte Corp. by 0.7% in the second quarter. CIBC Asset Management Inc now owns 13,037 shares of the biopharmaceutical company’s stock valued at $1,043,000 after buying an additional 87 shares during the period. Finally, Sumitomo Mitsui Asset Management Company LTD increased its stake in shares of Incyte Corp. by 0.9% in the second quarter. Sumitomo Mitsui Asset Management Company LTD now owns 11,453 shares of the biopharmaceutical company’s stock valued at $916,000 after buying an additional 97 shares during the period. Institutional investors own 92.32% of the company’s stock.

Incyte Corp. Company Profile

Incyte Corporation is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat medical needs, primarily in oncology. The Company focuses on the research and development program to explore the inhibition of enzymes called janus associated kinases (JAK).

5 Day Chart for NASDAQ:INCY

Receive News & Stock Ratings for Incyte Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corp. and related stocks with our FREE daily email newsletter.